It was found that (S)-6H-1-(5-isoquinolinesulfonyl)-2-hydroxymethyl-1-pyrrolidine and (S)-6H-1-(5- isoquinolinesulfonyl)-2-chloromethyl-1-pyrrolidine displayed excellent Rho inhibitory activity in previous work. Therefore, with these two compounds as lead compounds, we designed and synthesized their enantiomers in order to reveal the effects of chirality on the combination of inhibitor and Rho kinase. Their biological activity evaluation results indicated that the chirality of inhibitors indeed presented important influences on their Rho kinase inhibitory activities. Furthermore, several analogues of the lead compounds were designed and synthesized. It was found that the isostere, (S)-6H-1-(5-isoquinolinesulfonyl)-2-fluorinated-methyl-pyrrolidine (compound 7) exhibited much better Rho kinase inhibitory activity than the lead compounds and strongly promoted synapse formation. Thus, it is believed to be a potential candidate as Rho kinase inhibitors.
结果发现(S)-6H-1-(5-
异喹啉磺酰基)-2-羟甲基-1-
吡咯烷和(S)-6H-1-(5-
异喹啉磺酰基)-2-
氯甲基-1-
吡咯烷表现出优异的Rho以前工作中的抑制活性。因此,我们以这两种化合物为先导化合物,设计并合成了它们的对映体,以揭示手性对
抑制剂与Rho激酶结合的影响。
生物活性评价结果表明
抑制剂的手性确实对其Rho激酶抑制活性产生重要影响。此外,还设计并合成了先导化合物的几种类似物。结果发现,电子等排体(S)-6H-1-(5-
异喹啉磺酰基)-2-
氟化-甲基-
吡咯烷(化合物7)表现出比先导化合物更好的Rho激酶抑制活性,并强烈促进突触形成。因此,它被认为是 Rho 激酶
抑制剂的潜在候选者。